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Malignant peripheral nerve sheath tumours (MPNSTs) are highly malignant and resistant. Transformation might implicate up
regulation of epidermal growth factor receptor (EGFR). Fifty-two MPNST samples were studied for EGFR, Ki-67, p53, and
survivin expression by immunohistochemistry and for EGFR ampliﬁcation by in situ hybridization. Results were correlated with
clinical data. EGFR RNA was also quantiﬁed by RT-PCR in 20 other MPNSTs and 14 dermal neuroﬁbromas. Half of the patients
had a neuroﬁbromatosis type 1 (NF1). EGFR expression, detected in 86% of MPNSTs, was more frequent in NF1 specimens
and closely associated with high-grade and p53-positive areas. MPNSTs expressed more EGFR transcripts than neuroﬁbromas.
No ampliﬁcation of EGFR locus was observed. NF1 status was the only prognostic factor in multivariate analysis, with median
survivals of 18 and 43 months for patients with or without NF1. Finally, EGFR might become a new target for MPNSTs treatment,
especially in NF1-associated MPNSTs.
Copyright © 2008 S´ everine Tabone-Eglinger et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Malignant peripheral nerve sheath tumours (MPNSTs) are
Schwanncellneoplasmsthatarehighlyaggressive,frequently
lethal, and generally resistant to conventional radiation and
chemotherapy [1, 2].
Nearly half of these tumours arise in the context of
the inherited predisposition syndrome, neuroﬁbromatosis
type 1 (NF1), suggesting that inactivation of the NF1
tumour suppressor gene might be causally related to the
development of these cancers [3]. NF1 is a dominantly
inherited human disease aﬀecting one in 2500 to 3500
individuals [4]. NF1 is characterized by caf´ e-au-lait spots
(ﬂat pigmented skin lesions), Lish nodules (abnormality
of the iris), skeletal abnormalities, learning disabilities,
neuroﬁbromas, and increased risk of developing malignant
tumours of the central and peripheral nervous system [5].
NF1 is associated with mutations of the tumour suppressor
gene NF1, which encodes for the Ras-GTPase-activating
protein neuroﬁbromin [6–8].
Molecular events contributing to peripheral nerve
tumour development are unclear. In the context of NF1,
loss of neuroﬁbromin, the NF1 protein product, is believed
to be the earliest event, as patients inherit a mutated NF12 Sarcoma
allele and lose the second copy in the MPNST cells. Loss
of both copies was also observed in benign neuroﬁbromas.
It is likely that tumour suppressor mutations alone are
not suﬃcient, and that deregulation and/or mutations of
oncogenes are necessary to induce malignant transformation
of Schwann cells. The overexpression or mutation of the
tumoursuppressorgeneTP53observedinMPNSTssupports
the notion that p53 alterations play a role in their develop-
ment [9]. Several studies have demonstrated the central role
of epidermal growth factor receptor (EGFR) in malignant
transformation of Schwann cells [10–13]. To our knowledge,
only 12 cases of human MPNST have been studied for EGFR
by immunohistochemistry [10, 13]. In the present study,
we analyzed the expression of EGFR in the tumours of 52
patients with MPNST, and compared it with NF1 status and
survival.
2. MATERIALS AND METHODS
2.1. Patientsandsamples
Patients of the main series (n = 52) were all treated in
the Institut Gustave Roussy (IGR, Villejuif, France) between
1985 and 2005. Clinical records were reviewed by one of us
(R. Bahleda), with special attention to initial localization,
NF1 status, treatment and survival. Diagnosis of NF1 was
established according to the NIH criteria [14]. Most of the
patients had undergone surgery in another centre and were
secondary referred to IGR. Tumours were considered as
local stage, when R0 surgery was performed initially, and
locally advanced stage for R1 and R2 surgery. Only cases
with paraﬃn embedded MPNST samples were included in
the study. Histological review was realized for all included
patients by at least two pathologists (PT, MJTL, JFE) on
hematoxylin-eosin stained slides. Diagnosis of MPNST was
performed according to WHO criteria [15]. Grading of
the tumours was not performed, due to limited amounts
of paraﬃn embedded samples. Immunostaining with S100
protein (rabbit polyclonal, Dako, Carpenteria, Calif, USA)
and KIT (rabbit polyclonal, Dako) was performed when
necessary to conﬁrm diagnosis.
All 52 paraﬃn embedded samples were subjected to
immunohistochemistry; 8 of which were also analysed by
FISH/CISH.
Frozensamplesfrom20otherpatientswithMPNSTwere
used for the RNA analysis. Sixteen were from a previously
published series [16]a n df o u rf r o mL ´ eon B´ erard Centre
(Lyon,France).Frozencontrolsamplesfrom14patientswith
benign dermal neuroﬁbromas were also analyzed.
All samples were obtained from surgery performed
for diagnostic and/or therapeutic purpose, and were used
according to French ethical regulations.
2.2. Immunohistochemistry
Immunohistochemistry was performed on four micron
sections from paraﬃne m b e d d e dt u m o u rs a m p l e s ,a f t e r
antigen retrieval by heating at 95
◦Cf o r2 0m i n u t e si n1 0m M
citratebuﬀerpH6.Formousemonoclonalanti-EGFR(31G7,
Zymed, SouthSanFrancisco, Calif,USA, ﬁnaldilution 1/10),
P53 (DO-7, Novocastra, Newcastle upon Tyne, UK, ﬁnal
dilution 1/50), and anti-Ki-67 (Mib1 Dako, ﬁnal dilution
1/50), staining was revealed with LSAB kit (Dako). For anti-
Survivin (12C4, Dako, ﬁnal dilution 1/100) staining was
revealed with CSAII (Dako), according to manufacturer’s
instruction.
For EGFR staining, tumour cells were considered nega-
tive, when positive signals were detected on nontumour cells
(usually spindle cells and/or small nerves in the periphery
of the tumours); otherwise, staining was considered as not
interpretable.
2.3. Fluorescentinsituhybridization(FISH)
Eight paraﬃn embedded samples of the main series were
analyzed for EGFR ampliﬁcation. EGFR speciﬁc sequence
p r o b e( L S IE G F R )a n dc o n t r o lc h r o m o s o m ee n u m e r a t i o n
probe 7 (CEP7) were used according to the manufacturers’
recommended protocol (Vysis-Abbott Molecular Diagnos-
tics, Baar, Switzerland), but with some minor modiﬁcations.
The DNA probes and the sections of tissues were denatured
at 85
◦C for 5 minutes using a HYBrite instrument. An
additional wash in distilled water was added before counter-
staining and mounting with a solution of 4, 6-diamidino-2-
phenylindole (DAPI). The results are reported as the ratio
of average EGFR/CEP7 signals per nucleus. Signal ratios of
<2 were classiﬁed as nonampliﬁed (NA) and ≥2 as ampliﬁed
(A). In each section, at least 30 nuclei were counted for
signals.
2.4. Chromogenicinsituhybridization(CISH)
CISH experiments were performed, according to the proto-
col given by the supplier (Zymed), along with FISH to have
more information about sample morphology and to have





(Applied Biosystems, Foster City, Calif, USA) have been
described in detail elsewhere [16].
The precise amount of total RNA added to each reaction
mix (based on optical density) and its quality (i.e., lack
of extensive degradation) are both diﬃcult to assess. We
therefore also quantiﬁed transcripts of the endogenous RNA
control gene TBP (Genbank accession NM 003194), which
encodes the TATA box-binding protein. Each sample was
normalizedonthebasisofitsTBPcontent.Results,expressed
as N-fold diﬀerences in target gene expression relative to
the TBP gene, and termed “Ntarget,” were determined as
Ntarget = 2ΔCtsample, where the ΔCt value of the sample was
determined by subtracting the average Ct value of the target
gene from the average Ct value of the TBP gene.S´ everine Tabone-Eglinger et al. 3
The Ntarget values of the samples were subsequently
normalized such that the mean of the dermal neuroﬁbroma
Ntarget values was 1.
2.6. Statisticalanalysis
Quantitative data were expressed as mean ± standard devia-
tion; qualitative data as frequency and percent. Comparisons
of means were performed using Student’s t-test or Mann and
Whitney nonparametric test when necessary. Comparisons
of frequencies were performed using the Chi square test, or
Fisher’s exact test when necessary.
Log-rank tests were used to examine the relationship
between overall survival and the following variables: age,
gender,initiallocalization,NF1status,andEGFRexpression.
Variables with a statistical P value <.20 were entered into a
Cox model multivariate analysis. P value less than 0.05 was
considered signiﬁcant in multivariate analysis.
Statistical analyses were performed with the SAS 8.2
software package (SAS Institute Inc, Cary, NC, USA).
3. RESULTS
The mains clinical characteristics of the 52 patients with
MPNST are presented in Table 1. The mean age at time of
diagnosis was 23 ± 15 years, and the sex ratio was 30m/22f.
Tumours were localized in trunk, head or neck (n = 24), or
in the limbs (n = 28). Half of the patients (n = 26) had a
NF1, of whom nine had a familial history of NF1. The age at
diagnosis of MPNSTswas earlier in patients withNF1 (19±9
years) than in non-NF1 patients (27 ±18 years) (P = .04).
EGFR expression by tumour cells was detected by
immunohistochemistry in 36 out of the 42 (86%) valuable
patients with MPNST; percentages were higher in the NF1
subgroup (95% versus 75%; P = .06; Chi square test)
(see Table 1). Localization of EGFR within tumour cells was
either membranous, cytoplasmic, or both (see Figure 1). In
six cases, tumour cells were negative and 10 other cases were
not valuable and were thus excluded from the analysis.
Interestingly, the staining was heterogeneous throughout
the tumour in several cases (see Figure 2(a)). In these
cases, EGFR-positive cells were localized in “high-grade”
areas, deﬁned as areas with high-cellular density and high
mitotic index. In four of these cases, samples were available
to perform serial sections, and we conﬁrmed that EGFR-
positive areas segregate with high-grade features, as prolif-
erative index detected by Ki-67 expression, and in two cases
also with P53-positive areas (see Figure 2(b)). By contrast,
staining with survivin, which was positive in all the cases of
MPNST, was diﬀuse to all tumour areas (see Figure 3).
To conﬁrm, by another way, the high frequency of EGFR
overexpression in MPNSTs, we quantiﬁed EGFR transcripts
in an independent series of 20 MPNSTs using real time RT-
PCR, and compared it to 14 benign dermal neuroﬁbromas.
The mean of EGFR RNA level was higher in MPNSTs than in
benign dermal neuroﬁbromas (1.68±2.5v e r s u s1±0.4, NS),
andfour(25%)ofMPNSTsamplesshowedmarkedincreases
ofEGFRtranscripts(morethan3timeshigherthanthemean
for benign dermal neuroﬁbromas).
(a) (b)
Figure 1: EGFR expression in MPNSTs. In both cases, 100%
of tumour cells strongly expressed EGFR (brown). However, it
was detected either (a) within the cytoplasm or (b) on plasma






with high-grade Ki-67 and p53-positive (b) areas. Scale bar
represents 15µm.
To determine whether overexpression of EGFR protein
and RNA might be related to an ampliﬁcation of EGFR
locus, we performed CISH and FISH analysis on eight
MPNSTsamplesofthemainseries(R72,R74,R78,R84,R85,
R86, R92, R94, R111, R116), whose expression was either
homogeneous (n = 2) or heterogeneous (n = 6). None of
the tumour had evidence of EGFR ampliﬁcation. The mean
numberofspotdetectedinthenucleiof40to60tumourcells
by sample stained by CISH was 2.42 [range from 2.1 to 3.3].
I no n l yo n ec a s e ,5t o6s p o t sw e r ed e t e c t e di ns o m et u m o u r
cells, however FISH revealed a polysomy of chromosome 7
for this tumour (see Figure 4).4 Sarcoma
Table 1: Characteristics of the 52 patients with MPNST. NF1: Neuroﬁbromatosis type 1; Spo: sporadic form of NF1 (no familial history),
Fam: familial form of NF1; L: local stage; LA: locally advanced stage; Met: metastatic stage. A: alive. D: dead; +: positive staining; −:n e g a t i v e
staining; n.e.: not evaluable staining.
Patient n◦ NF1 Age/gender Stage init Localization EGFR
R72 no 37/m LA Neck +
R69 no 12/m LA Thigh +
R92 no 11/w LA Brachial plexus +
R78 no 28/w L Left arm +
R94 no 52/m L Ethmoid +
R86 no 33/f L Arm +
R87 no 3/f L Tibial nerve +
R77 no 71/f L Median nerve +
R84 no 19/m LA Pelvis +
R90 no 47/m L Right thigh +
R74 no 16/f L Foot +
R85 no 48/f L Forearm +
R93 no 7/f L Mandible +
R79 no 30/m L Wrist +
R89 no 18/f LA Infratemporal fossa +
R88 no 26/m L Left calf 0
R75 no 50/f LA Retroperitoneum 0
R76 no 23/m L Frontal region 0
B1027 no 15/m LA Retroperitoneum, pelvis 0
R73 no 7/m LA Neck 0
B1499 no 60/m LA Mediastinum n.e.
R80 no 14/f L Left orbit n.e.
B1044 no 7/m L Calf n.e.
R95 no 20/m Met Hand n.e.
R81 no 46/m L Forearm n.e.
B1463 no 19/m LA Armpit n.e.
R123 Fam 15/m L Median nerve +
R118 B Fam 11/f LA Brachial plexus +
B1357 Spo 16/m LA Sciatic nerve +
R107 Spo 33/m L Neck +
R111 Spo 13/f LA Thigh +
B1064 Spo 44/f L Thigh +
R116 Spo 10/m LA Arm +
R98 Spo 23/f L Calf +
B2387 Spo 29/m LA Supraclavicular region +
R122 Fam 19/f LA Groin +
R104 Spo 25/m L Left calf +
R97 Spo 17/m LA Left iliac +
B1400 Fam 20/m LA Chest wall +
R105 Spo 13/m LA Abdominal wall +
R96 Spo 23/m LA Sciatic nerve buttock +
R102 Spo 23/m M´ eta Retroperitoneum +
R101 Spo 26/m LA Retroperitoneum +
B1399 Spo 5/m LA Urinary bladder +
R114 Spo 7/m LA Thigh +
B1148 Fam 17/f L Thigh +
bloc t Spo 32/f L Thigh +
B1793 Fam 32/f L Thigh 0
R127 Fam 11/f LA Left thigh (sciatic) n.e.
R119 Fam 10/m LA Retroperitoneum n.e.
R125 Fam 11/f LA Upper n.e.
B1599 Spo 20/f LA Pelvis n.e.S´ everine Tabone-Eglinger et al. 5
Figure 3: Homogenous expression of survivin in MPNSTs. Scale
b a rr e p r e s e n t s2 0µm.
(a)
(b)
Figure 4: CISH and FISH analysis on the R84 MPNST sample.
(a) The mean number of spot detected in the nuclei of 40 to 60
tumour cells in this sample stained by CISH was 3.3. (b) FISH
conﬁrmed multiple spot of EGFR (red) but revealed a polysomy of
chromosome 7 (green) for this tumour. Scale bar represents 5µm.
All the patients underwent surgical resection of the
tumour, except two whose diagnosis was performed at
metastatic stage. Two other patients were lost of view, few
days after initial diagnosis, and were thus excluded for
survival analysis. Kaplan-Meyer analysis of overall survival
revealedthatthelocalstage(localorlocallyadvanced)aswell
as NF1 status had a poor outcome (P = .0005 and P = .008,
resp.), while age at diagnosis, gender, and EGFR expression
had not. Multivariate analysis revealed that only NF1 status
persistedasanindependentprognosticfactor(P = .02),with
a hazard ratio at 2.7 [1.2–6.2]. Median survivals of patients
with or without NF1 were 18 and 43 months, respectively,
and the 5-year survival was 11% and 45%, respectively.
4. DISCUSSION
In this well-deﬁned series of 52 patients with MPNSTs,
we have shown by immunohistochemistry that EGFR was
expressed in 86% (71–94%) of cases. In the independent
series of 20 MPNST RNAs, we observed marked EGFR RNA
overexpression in 4 (25%) MPNSTs (>3 times the levels in
benigndermalneuroﬁbromas).Ourresultsconﬁrmprevious
detection of EGFR in 8/12 cases by immunohistochemistry
[10, 13], in 6/7 patients by western blotting [13], as well
as EGFR mRNA in 16/42 cases [17]. In the latter study,
NF1 patients were more frequently positive for EGFR RNA
expression (12/25 versus 4/17 in non NF1 patients). Analysis
of human MPNST cell lines also revealed a stronger and
more diﬀuse expression of EGFR in cells lines derived from
NF1 as compared to non-NF1 patients [18]. EGFR was also
more frequently expressed in NF1 patients in our series
(95% versus 75%; P = .03). Immunohistochemical EGFR
detection data has been reported in numerous publications
with good staining sensitivity and speciﬁcity on paraﬃn
embedded tissue samples.
Overexpression of both protein and RNA suggests pre-
translational regulation of EGFR in MPNSTs. Ampliﬁcation
ofgenelocusisacommonmechanismofregulationofEGFR
in other tumours such as head and neck squamous cell
carcinomas [19], non-small-cell lung carcinomas [20], and
colorectal carcinomas [21]. In MPNSTs, EGFR ampliﬁcation
has previously been reported in 5 out of 17 patients [22].
In this study, a “low-level” ampliﬁcation was described
with scattered cells containing 6–12 spots, accompanied by
polysomy 7 in three cases. Another group failed to detect
EGFR ampliﬁcation in four cases, although 1-2 extra copies
were seen in one of these cases [23]. Here, we conﬁrm these
latter results in eight patients. Thus, EGFR overexpression in
the majority of MPNSTs is not due to ampliﬁcation of the
EGFR locus at 7p12. Normal Schwann cells do not express
EGFR, while NF1 mutation leads to EGFR overexpression
in these cells [12]. NF1 loss of function may thus enhance
transcription of EGFR.
Mice with heterozygous deletions of NF1 (Nf1
+/−)d o
not have an increased incidence of nerve tumours; however
whenthesemicealsocarryaheterozygousmutationsofTP53
(Nf1
+/− p53+/−) they develop sarcomas and brain tumours
[24, 25]. EGFR is frequently expressed in Schwann cell lines
derived from these (Nf1
+/− p53+/−) mice. Cell growth in
theselines isgreatlystimulated byEGFand blocked byEGFR
antagonists[11].DecreasedEGFRsignalinginNf1
+/− p53+/−
mice reduced their mortality [12]. In the present series, we
showed that high expression of EGFR was present in the
high-gradeareasofthetumours,appearingtocolocalizewith
Ki-67 in all cases and with p53 in half of the cases. In several
cases, a strong EGFR expression of in highly cellular regions,
contrasting with negativity in other regions, has already been
described in one NF1 patient [10]. Thus, as for animal and
invitromodels,ourdatasuggestthatEGFRoverexpressionis
associated with malignant transformation of Schwann cells.
However, NF1 status was the only prognostic factor in
multivariate analysis, with median survivals of 18 and 43
months for patients with or without NF1. EGFR expression,6 Sarcoma
although higher in NF1 patients, did not appear as a
prognostic factor for MPNST, nor did local stage, age at
diagnosis, or gender.
Overexpression of survivin mRNA in MPNSTs has
been observed independently by three groups [16, 17, 26].
Supervised analysis of gene expression proﬁling of MPNSTs
revealed that EGFR-positive and -negative tumours had a
speciﬁc gene expression signatures [17]. Interestingly, these
authors showed that EGFR-positive tumours had a higher
expression of Ki-67 and survivin transcripts. We conﬁrmed
herein by immunohistochemistry, that bring supplementary
data about cellular localization of the expression, that
survivinwasexpressedbymalignantSchwanncells.But,con-
trasting with EGFR, survivin expression was not restricted to
high-grade areas of the tumours.
The prognosis of MPNSTs is poor, with only 23% of
living individuals 10 years after diagnosis [27]. Post-surgical
irradiation, as no eﬀect on overall survival and no eﬀective
chemotherapeutic regimens, is available [1]. In our series,
the mean age of diagnosis was 23 ± 15 years and the median
survival was 30 months. Thus, there is considerable interest
in establishing the mechanisms responsible for MPNST
tumourigenesis and using this information to develop new,
more eﬀective, therapies. Targeted therapies using mon-
oclonal antibodies against EGFR are highly eﬀective in
several human cancer [28]. So far, most of the patients
treated with a monoclonal antibody anti-EGFR Cetuximab
(Erbitux, Lyon, France) suﬀer from colorectal [29]o rl u n g
[30] cancers. Recently, Cetuximab was successfully used to
preventthedevelopmentofneuroﬁbromasinamousemodel
of NF1 [31]. Several groups showed the implication of EGFR
expression in malignant transformation of Schwann cells
in cell lines and/or mouse models. Our results obtained
in a large series of human MPNSTs conﬁrmed these data.
Tumours with tyrosine kinase receptor overexpression have
been successfully treated with targeted therapies, as in
gastrointestinal stromal tumours, which express KIT and
may be treated with Imatinib [32]. Lung adenocarcinomas,
in which the expression of EGFR has no prognostic value
[33], may also be treated with geﬁtinib or erlotinib. Thus,
the overexpression of EGFR in 95% of NF1 patients with
MPNST and the very poor prognosis of these young patients
shown in the present study suggest that new therapies
targeting EGFR might be interesting for these patients.
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